Announcement on the Election of the Board of Directors

Securities Code: 002412 Securities Abbreviation: Hansen Pharmaceutical Announcement No.: 2026-005 Hunan Hansen Pharmaceutical Co., Ltd. Announcement on the Election of the Board of Directors The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and are free from false records, misleading statements, or major omissions. Hunan Hansen Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company")'s sixth Board of Directors is nearing the end of its term. In accordance with the Company Law, the Measures for the Administration of Independent Directors of Listed Companies, the Listing Rules of the Shenzhen Stock Exchange, and other relevant laws, regulations, normative documents, and the Articles of Association, the Board of Directors will hold an election for its next term. On April 24, 2026, the Company convened the eleventh meeting of the sixth Board of Directors, which deliberated and approved the "Proposal on the Election of the Board of Directors of the Company." The relevant matters are hereby announced as follows: I. Board of Directors Election Status The seventh Board of Directors will be composed of seven directors, including independent directors, non-independent directors, and employee representative directors. At the eleventh meeting of the sixth Board of Directors, the Board of Directors agreed to nominate Mr. Liu Zhengqing, Mr. Liu Bingyang, and Mr. Ao Ling Song as candidates for non-independent directors of the seventh Board of Directors. Mr. Zeng Jianguo, Ms. Shen Lingfang, and Ms. Chen Chen are nominated as candidates for independent directors of the seventh Board of Directors, with Ms. Shen Lingfang being a professional in accounting. The resumes of the above director candidates are detailed in the appendix. Mr. Zeng Jianguo, a nominated independent director candidate, has obtained the qualification certificate for independent directors recognized by the Shenzhen Stock Exchange. Ms. Shen Lingfang and Ms. Chen Chen have not yet obtained independent director qualification certificates, but they have signed written commitments to participate in the next independent director qualification training and obtain the training certificate recognized by the Shenzhen Stock Exchange. The Nomination Committee of the Company's Board of Directors has reviewed the eligibility of the above director candidates and believes that the above director candidates do not have any circumstances that prohibit them from serving as directors of the Company as stipulated in the Company Law and the Articles of Association, have not been penalized by the China Securities Regulatory Commission or other relevant authorities, and have not been disciplined by the stock exchange, nor do they have any other circumstances that the stock exchange deems unsuitable for serving as directors of a listed company. The Company's shareholders' meeting will elect non-independent directors and independent directors separately using the cumulative voting system. The six directors elected by the shareholders' meeting, together with one employee representative director elected by the Company's employee representative assembly, will form the seventh Board of Directors of the Company, with a term of three years from the date of approval by the Company's shareholders' meeting. II. Other Matters The number of director candidates meets the requirements of the Company Law and the Articles of Association. The total number of directors who concurrently hold senior management positions and employee representative directors among the proposed directors shall not exceed one-half of the total number of directors, and the number of independent directors shall not be less than one-third of the total number of board members. To ensure the normal operation of the Board of Directors, the sixth Board of Directors will continue to perform its duties and responsibilities as directors in accordance with laws, regulations, normative documents, and the Articles of Association before the new Board of Directors takes office. The Company expresses its sincere gratitude to all directors of the sixth Board of Directors for their diligence and dedication during their term of office and their contributions to the Company's development. Hereby announced. Hunan Hansen Pharmaceutical Co., Ltd. Board of Directors 2026 April 28 Appendix: Resumes of Candidates for Directors of the Seventh Board of Directors I. Resumes of Non-Independent Director Candidates Mr. Liu Zhengqing: Born in October 1964, Chinese nationality, no permanent overseas residence, Master's degree. He previously served as workshop director and deputy factory director of Yiyang Pharmaceutical Factory, Chairman and General Manager of Hunan Yiyang Pharmaceutical Co., Ltd., Executive Deputy General Manager of Hunan Hansen Pharmaceutical Co., Ltd., and Vice Chairman and President of Hunan Hansen Pharmaceutical Co., Ltd. He is currently the Chairman and President of Hunan Hansen Pharmaceutical Co., Ltd. As of the disclosure date, Mr. Liu Zhengqing directly holds 1.42% of the Company's shares. He has no relationship with shareholders holding more than 5% of the Company's shares, the actual controller, or other directors and senior management personnel of the Company. Mr. Liu Zhengqing does not have any circumstances that prohibit him from holding relevant positions as stipulated in the Company Law, the Shenzhen Stock Exchange Stock Listing Rules, and the Shenzhen Stock Exchange Listed Company Self-Regulatory Guidelines No. 1 - Norms for the Operation of Main Board Listed Companies. He has not been identified as a market entrant by the China Securities Regulatory Commission and has not yet been de-listed. He has not been publicly identified by the stock exchange as unsuitable for serving as a director or senior management personnel of a listed company. He has not received administrative penalties from the China Securities Regulatory Commission in the past three years. He has not been publicly censured or notified three or more times by the stock exchange in the past three years. He has not been investigated by judicial authorities for suspected crimes or investigated by the China Securities Regulatory Commission for suspected violations of laws and regulations with no clear conclusion yet. According to inquiries, Mr. Liu Zhengqing has never been publicly disclosed on the China Securities Regulatory Commission's illegal and untrustworthy information inquiry platform for the securities and futures market or included in the list of persons subject to enforcement by the people's court as a dishonest judgment debtor, and meets the relevant legal and regulatory requirements for assuming office. Mr. Liu Bingyang: Born in January 1991, Chinese nationality, no permanent overseas residence, Bachelor's degree. He previously served as Deputy Director of the Investment and Financing Department of Hainan Hansen Holdings (Limited Partnership). He is currently the Executive Director and General Manager of Hunan Dalin Hansen Private Equity Fund Management Co., Ltd., a director of Tuopu Precision Intelligent Manufacturing Co., Ltd., and a director of Hunan Hansen Pharmaceutical Co., Ltd. As of the disclosure date, Mr. Liu Bingyang does not hold any shares in the Company. He is the son of the actual controller of the Company. He has no relationship with other directors. Mr. Liu Bingyang does not have any circumstances that prohibit him from holding relevant positions as stipulated in the Company Law, the Shenzhen Stock Exchange Stock Listing Rules, and the Shenzhen Stock Exchange Listed Company Self-Regulatory Guidelines No. 1 - Norms for the Operation of Main Board Listed Companies. He has not been identified as a market entrant by the China Securities Regulatory Commission and has not yet been de-listed. He has not been publicly identified by the stock exchange as unsuitable for serving as a director or senior management personnel of a listed company. He has not received administrative penalties from the China Securities Regulatory Commission in the past three years. He has not been publicly censured or notified three or more times by the stock exchange in the past three years. He has not been investigated by judicial authorities for suspected crimes or investigated by the China Securities Regulatory Commission for suspected violations of laws and regulations with no clear conclusion yet. According to inquiries, Mr. Liu Bingyang has never been publicly disclosed on the China Securities Regulatory Commission's illegal and untrustworthy information inquiry platform for the securities and futures market or included in the list of persons subject to enforcement by the people's court as a dishonest judgment debtor, and meets the relevant legal and regulatory requirements for assuming office. Mr. Ao Ling Song: Born in October 1972, Chinese nationality, no permanent overseas residence, Junior College degree. He previously served as Regional Manager of Hunan Zhengqing Group Pharmaceutical Co., Ltd., General Manager of Simo Tang Products and Deputy General Manager of Marketing at Hunan Hansen Pharmaceutical Co., Ltd., and Deputy General Manager of Marketing at Hunan Zhongda Wuma Pharmaceutical Co., Ltd. He is currently a director and Vice President of Hunan Hansen Pharmaceutical Co., Ltd. As of the disclosure date, Mr. Ao Ling Song does not hold any shares in the Company. He has no relationship with shareholders holding more than 5% of the Company's shares, the actual controller, or other directors and senior management personnel of the Company. Mr. Ao Ling Song does not have any circumstances that prohibit him from holding relevant positions as stipulated in the Company Law, the Shenzhen Stock Exchange Stock Listing Rules, and the Shenzhen Stock Exchange Listed Company Self-Regulatory Guidelines No. 1 - Norms for the Operation of Main Board Listed Companies. He has not been identified as a market entrant by the China Securities Regulatory Commission and has not yet been de-listed. He has not been publicly identified by the stock exchange as unsuitable for serving as a director or senior management personnel of a listed company. He has not received administrative penalties from the China Securities Regulatory Commission in the past three years. He has not been publicly censured or notified three or more times by the stock exchange in the past three years. He has not been investigated by judicial authorities for suspected crimes or investigated by the China Securities Regulatory Commission for suspected violations of laws and regulations with no clear conclusion yet. According to inquiries, Mr. Ao Ling Song has never been publicly disclosed on the China Securities Regulatory Commission's illegal and untrustworthy information inquiry platform for the securities and futures market or included in the list of persons subject to enforcement by the people's court as a dishonest judgment debtor, and meets the relevant legal and regulatory requirements for assuming office. II. Resumes of Independent Director Candidates Mr. Zeng Jianguo: Born in November 1965, Chinese nationality, no permanent overseas residence, Ph.D., Professor. He previously served as General Manager of Hunan Hongshengtang Pharmaceutical Co., Ltd. and General Manager of Hunan Jiuhui Modern Chinese Medicine Co., Ltd. He is currently a Professor in the Department of Pharmacy, College of Veterinary Medicine, Hunan Agricultural University, and Director of the Yuefulou Laboratory for Chinese Herbal Medicine Variety Innovation. As of the disclosure date, Mr. Zeng Jianguo does not hold any shares in the Company. He has no relationship with shareholders holding more than 5% of the Company's shares, the actual controller, or other directors and senior management personnel of the Company. Mr. Zeng Jianguo does not have any circumstances that prohibit him from holding relevant positions as stipulated in the Company Law, the Shenzhen Stock Exchange Stock Listing Rules, and the Shenzhen Stock Exchange Listed Company Self-Regulatory Guidelines No. 1 - Norms for the Operation of Main Board Listed Companies. He has not been identified as a market entrant by the China Securities Regulatory Commission and has not yet been de-listed. He has not been publicly identified by the stock exchange as unsuitable for serving as a director or senior management personnel of a listed company. He has not received administrative penalties from the China Securities Regulatory Commission in the past three years. He has not been publicly censured or notified three or more times by the stock exchange in the past three years. He has not been investigated by judicial authorities for suspected crimes or investigated by the China Securities Regulatory Commission for suspected violations of laws and regulations with no clear conclusion yet. According to inquiries, Mr. Zeng Jianguo has never been publicly disclosed on the China Securities Regulatory Commission's illegal and untrustworthy information inquiry platform for the securities and futures market or included in the list of persons subject to enforcement by the people's court as a dishonest judgment debtor, and meets the relevant legal and regulatory requirements for assuming office. Ms. Shen Lingfang: Born in November 1973, Chinese nationality, no permanent overseas residence, Master's degree, Certified Public Accountant, China Project Data Analyst, Senior Accountant. She previously served as a partner at Hunan Dayu United Certified Public Accountants Firm, Financial Controller of Chongqing Hongling Hospital and Chongqing Hongling Medical Co., Ltd., and Adjunct Professor at Hunan Finance and Economics University. She is currently a director and financial controller of Hunan Sheng Hui Investment Management Co., Ltd., a director of Chongqing Hongling Medical Co., Ltd., and the person in charge of Hunan Tianyinghe Certified Public Accountants Firm (General Partnership). As of the disclosure date, Ms. Shen Lingfang does not hold any shares in the Company. She has no relationship with shareholders holding more than 5% of the Company's shares, the actual controller, or other directors and senior management personnel of the Company. Ms. Shen Lingfang does not have any circumstances that prohibit her from holding relevant positions as stipulated in the Company Law, the Shenzhen Stock Exchange Stock Listing Rules, and the Shenzhen Stock Exchange Listed Company Self-Regulatory Guidelines No. 1 - Norms for the Operation of Main Board Listed Companies. She has not been identified as a market entrant by the China Securities Regulatory Commission and has not yet been de-listed. She has not been publicly identified by the stock exchange as unsuitable for serving as a director or senior management personnel of a listed company. She has not received administrative penalties from the China Securities Regulatory Commission in the past three years. She has not been publicly censured or notified three or more times by the stock exchange in the past three years. She has not been investigated by judicial authorities for suspected crimes or investigated by the China Securities Regulatory Commission for suspected violations of laws and regulations with no clear conclusion yet. According to inquiries, Ms. Shen Lingfang has never been publicly disclosed on the China Securities Regulatory Commission's illegal and untrustworthy information inquiry platform for the securities and futures market or included in the list of persons subject to enforcement by the people's court as a dishonest judgment debtor, and meets the relevant legal and regulatory requirements for assuming office. Ms. Chen Chen: Born in February 1985, Chinese nationality, no permanent overseas residence, Master's degree, National Second-Level Psychological Counselor, practicing lawyer. She worked at Hunan Normal University for eight years and is currently the Executive Director and Founding Partner of Hunan Hongnian Law Firm. As of the disclosure date, Ms. Chen Chen does not hold any shares in the Company. She has no relationship with shareholders holding more than 5% of the Company's shares, the actual controller, or other directors and senior management personnel of the Company. Ms. Chen Chen does not have any circumstances that prohibit her from holding relevant positions as stipulated in the Company Law, the Shenzhen Stock Exchange Stock Listing Rules, and the Shenzhen Stock Exchange Listed Company Self-Regulatory Guidelines No. 1 - Norms for the Operation of Main Board Listed Companies. She has not been identified as a market entrant by the China Securities Regulatory Commission and has not yet been de-listed. She has not been publicly identified by the stock exchange as unsuitable for serving as a director or senior management personnel of a listed company. She has not received administrative penalties from the China Securities Regulatory Commission in the past three years. She has not been publicly censured or notified three or more times by the stock exchange in the past three years. She has not been investigated by judicial authorities for suspected crimes or investigated by the China Securities Regulatory Commission for suspected violations of laws and regulations with no clear conclusion yet. According to inquiries, Ms. Chen Chen has never been publicly disclosed on the China Securities Regulatory Commission's illegal and untrustworthy information inquiry platform for the securities and futures market or included in the list of persons subject to enforcement by the people's court as a dishonest judgment debtor, and meets the relevant legal and regulatory requirements for assuming office.